<--- Back to Details
First PageDocument Content
Radiobiology / Radioactivity / Particle physics / Proton therapy / Bragg peak / Positron emission tomography / Radiation therapy / Ionizing radiation / Proton beam / Medicine / Radiation oncology / Medical physics
Date: 2013-10-23 10:06:41
Radiobiology
Radioactivity
Particle physics
Proton therapy
Bragg peak
Positron emission tomography
Radiation therapy
Ionizing radiation
Proton beam
Medicine
Radiation oncology
Medical physics

18 Feasibility  of  using   O-­‐enriched  phantoms  for  PET  range   verificaBon  of  proton  therapy  treatment  planning     1

Add to Reading List

Source URL: www.kiragrogg.com

Download Document from Source Website

File Size: 2,10 MB

Share Document on Facebook

Similar Documents

What Is PET? Positron Emission Tomography (PET) is a non-invasive form of medical imaging approved by Medicare for diagnosis and management of several forms of cancer including: 	 Lung Cancer

What Is PET? Positron Emission Tomography (PET) is a non-invasive form of medical imaging approved by Medicare for diagnosis and management of several forms of cancer including: Lung Cancer

DocID: 1uv0l - View Document

Determining the diagnostic kinetics of viral encephalitis using positron emission tomography (PET) in Münster Nicholas King, Discipline of Pathology, Bosch Institute, School of Medical Sciences, Sydney Medical School, U

Determining the diagnostic kinetics of viral encephalitis using positron emission tomography (PET) in Münster Nicholas King, Discipline of Pathology, Bosch Institute, School of Medical Sciences, Sydney Medical School, U

DocID: 1rQ7R - View Document

Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients. 89Zr-  Bernard M. Gburek1, Anthony

Histopathologic Features that Influence the Detection of Occult Lymph Node Metastasis Using PET/CT Imaging with Anti-PSMA Df-IAB2M in Newly Diagnosed High Risk Prostate Cancer Patients. 89Zr- Bernard M. Gburek1, Anthony

DocID: 1rqYg - View Document

THE U~VERSITY OF NEW MEXICO COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO

THE U~VERSITY OF NEW MEXICO COLLEGE OF PHARMACY ALBUQUERQUE, NEW MEXICO

DocID: 1riLo - View Document

Microsoft Word - 25-32_FINAL_SN0302.doc

Microsoft Word - 25-32_FINAL_SN0302.doc

DocID: 1rbdW - View Document